Walleye Trading LLC Geron Corp Transaction History

Walleye Trading LLC

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$1.75 - $3.44 $113,046 - $222,217	-64,598 Reduced 96.16%	2,582 $8,000
Q4 2023 Feb 14, 2024	SELL	$1.74 - $2.31 $132,187 - $175,490	-75,970 Reduced 53.07%	67,180 $141,000
Q3 2023 Nov 14, 2023	BUY	$2.11 - $3.28 $240,440 - $373,765	113,953 Added 390.29%	143,150 $303,000
Q2 2023 Aug 14, 2023	SELL	$1.97 - $3.69 $365,939 - $685,439	-185,756 Reduced 86.42%	29,197 $93,000
Q1 2023 May 15, 2023	BUY	$2.14 - $3.4 $459,999 - $730,840	214,953 New	214,953 $466,000
Q3 2022 Nov 14, 2022	BUY	$1.67 - $2.94 $139,491 - $245,572	83,528 New	83,528 $195,000
Q2 2021 Aug 16, 2021	SELL	$1.25 - $1.83 $19,435 - $28,452	-15,548 Closed	0 $0
Q1 2021 May 17, 2021	SELL	$1.52 - $2.1 $55,618 - $76,841	-36,591 Reduced 70.18%	15,548 $25,000
Q4 2020 Feb 16, 2021	SELL	$1.55 - $2.05 $104,349 - $138,010	-67,322 Reduced 56.35%	52,139 $83,000
Q3 2020 Nov 16, 2020	BUY	$1.59 - $2.19 $189,942 - $261,619	119,461 New	119,461 $208,000
Q4 2018 Feb 14, 2019	SELL	$0.98 - $1.85 $38,323 - $72,346	-39,106 Closed	0 $0
Q3 2018 Nov 14, 2018	BUY	$1.76 - $6.38 $68,826 - $249,496	39,106 New	39,106 $69,000

275

491M

1.87M

690K

Ticker GERN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 377,819,008
Market Cap $1.54B
Description
Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hemat...

Get notified when there are updates to the investment portfolio of Walleye Trading LLC, based on Form 13F filings with the SEC.

Stay updated on Walleye Trading LLC with notifications on news.